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Background/Aims: Bone marrow-derived mesenchymal 
stem cells (BM-MSCs) have shown beneficial effects in ex-
perimental colitis models, but the underlying mechanisms 
are not fully understood. We investigated the long-term ef-
fects of BM-MSCs, particularly in mice with chronic colitis. 
Methods: Chronic colitis was induced by administering 3% 
dextran sulfate sodium (DSS) in a series of three cycles. BM-
MSCs were injected intravenously into DSS-treated mice 
three times during the first cycle. On day 33, the therapeutic 
effects were evaluated with clinicopathologic profiles and 
histological scoring. Inflammatory mediators were measured 
with real-time polymerase chain reaction. Results: Systemic 
infusion of BM-MSCs ameliorated the severity of colitis, and 
body weight restoration was significantly promoted in the BM-
MSC-treated mice. In addition, BM-MSC treatment showed 
a sustained beneficial effect throughout the three cycles. 
Microscopic examination revealed that the mice treated with 
BM-MSCs had fewer inflammatory infiltrates, a lesser extent 
of inflammation, and less crypt structure damage compared 
with mice with DSS-induced colitis. Anti-inflammatory cyto-
kine levels of interleukin-10 were significantly increased in 
the inflamed colons of BM-MSC-treated mice compared with 
DSS-induced colitis mice. Conclusions: Systemic infusion 
of BM-MSCs at the onset of disease exerted preventive and 
rapid recovery effects, with long-term immunosuppressive 
action in mice with repeated DSS-induced chronic colitis. (Gut 
Liver 2016;10:412-419)
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INTRODUCTION
Inflammatory bowel disease (IBD), ulcerative colitis (UC) and 
Crohn’s disease (CD), are chronic relapsing inflammatory dis-
orders of the gastrointestinal tract. Although the pathogenesis 
of UC and CD is still unclear, growing evidence has shown 
that epithelial barrier defects and dysregulated immune system 
reactions in genetically susceptible individuals contribute to 
sustained mucosal inflammation.1,2 An inappropriate adaptive 
immune response activated by commensal microbes is known 
to directly cause tissue damage, and recent studies report that 
clearance of over-reactive or autoreactive T-cells and balance 
of regulatory and effector T cells (Th1 and Th2) are disturbed 
in patients with IBD.2,3 As for the treatment of IBD, because the 
need for bowel resection due to failure of medical treatments 
is remained yet, there is an unmet demand for new therapeutic 
approaches targeting uncontrolled inflammatory activity to 
complement the limited efficacy of current immunosuppressive 
and biologic agents.4-6
 Candidates for new alternative treatments include cell ther-
apy. The first use of hematopoietic stem cells (HSC) as a treat-
ment for IBD was reported in patients with CD, who remained 
in remission after an HSC transplant for non-Hodgkin’s lym-
phoma.7 With the development of autologous bone marrow (BM) 
stem cell transplantation for CD,8 mesenchymal stem cells (MSCs) 
have been also reported as an effective source of cell therapy.
MSCs, derived from various tissues like BM and adipose tis-
sue, are a heterogeneous population of stromal stem cells that 
can self-renew and differentiate into different cell types, such 
as bone, cartilage, and fat cells.9 In addition to their ability to 
promote tissue regeneration from damaged tissue progenitors,9,10 
MSCs have been shown to regulate both innate and adaptive 
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immune responses by inhibiting T cell proliferation, B cell func-
tion, and dendritic cell maturation.10-12 Therefore, MSCs are 
emerging as a candidate for treatment of immune-mediated 
disease, including IBD. Indeed, an in vivo immunosuppressive 
effect was reported in 94% of patients with acute, severe graft-
versus-host disease who were treated with intravenous infusions 
of MSCs.13,14 In addition, with beneficial effect of MSCs in ex-
perimental colitis models,15-17 some clinical trials demonstrated 
positive results of MSCs therapy in Crohn’s perianal fistula and 
refractory luminal CD.18,19 However, most experiments have fo-
cused on the prevention and improvement of inflammation in a 
relatively short period after injection of MSCs and the underly-
ing mechanisms for the beneficial effects of MSCs are not yet 
fully understood. Therefore, we investigated the long-term effect 
of BM-MSCs in mice with chronic colitis induced by repeated 
administration of dextran-sulfate sodium (DSS).
MATERIALS AND METHODS
1. Animals
Female C57BL/6 mice (aged 8 weeks, weighing 17 to 21 g) 
were purchased from The Jackson Laboratory (Bar Harbor, ME, 
USA; http://www.jax.org). Mice were housed under specific 
pathogen-free conditions in a controlled temperature (24oC) and 
12–12 hour light–dark cycle and provided standard diet and 
water ad libitum. All animal experiments were approved by the 
Yonsei University Institutional Animal Care and Use Committee 
(approval number: 09-093-3) and performed according to the 
Guide for the Care and Use of Laboratory Animal (National Re-
search Council, USA, 2010).
2. BM-MSCs isolation and culture
Green fluorescent protein-transgenic (GFP-Tg) C57BL/6 
mouse BM-MSCs were isolated and cultured as described previ-
ously.20 The BM cells were obtained by flushing the femurs, tib-
ias, and iliac crests from 6-week-old mice with phosphate buff-
ered saline (PBS) supplemented with 2% fetal bovine serum (FBS; 
HyClone Laboratories Inc., Logan, UT, USA). The collected cells 
were cultured and maintained in a 75-cm2 culture flask contain-
ing Dulbecco’s modified Eagle medium (HyClone Laboratories 
Inc.) supplemented with 10% FBS, 100 U/mL penicillin (HyClone 
Laboratories Inc.), and 100 g/mL streptomycin (HyClone Labo-
ratories Inc.). Nonadherent cells were removed after 3 days, and 
only adherent cells were maintained in culture for 2 to 3 weeks 
until almost confluent. Then, adherent cells were detached using 
0.25% trypsin-ethylenediaminetetraacetic acid (HyClone Labo-
ratories Inc.). Subsequent passaging and seeding of the cells was 
performed at a density of 1×107 cells.
3. Colitis induction and experimental design
Chronic colitis was induced by administering 3% (w/v) DSS 
(molecular weight: 36,000 to 50,000 Da; MP Biochemicals, 
Santa Ana, CA, USA) via drinking water in a cyclic manner, 
which consisted of three cycles (4 days/cycle) of DSS and 6 days 
of normal drinking water ad libitum.21 GFP-Tg mice BM-MSCs 
(1×107 cells/200 µL) were injected intravenously into the DSS-
treated mice (n=5) on days 1, 3, and 5 during the first cycle 
(BM-MSC-treated group). Dosage and frequency of BM-MSCs 
were determined on the basis of our preliminary data and previ-
ous studies.16,17 In the control group, DSS-treated mice received 
PBS (n=5). All mice were sacrificed at day 33 after being fed 
DSS water, and the colon was processed for histological analysis 
or frozen in liquid nitrogen for RNA extraction. The therapeutic 
effect of BM-MSC treatment was evaluated by clinicopathologic 
profiles of body weight, colon length, and histological scoring.
4. Histological analysis
The entire colon was removed from the cecum to the anus, 
fixed in 4% paraformaldehyde, embedded in paraffin, and sliced 
into 4-µm sections. After hematoxylin and eosin (H&E) stain-
ing, histological analysis was performed in a blind manner. The 
following three parameters were studied as described previously:22 
inflammation severity (0=none, 1=mild, 2=moderate, and 3=se-
vere), inflammation extent (0=none, 1=mucosa, 2=mucosal and 
submucosa, and 3=transmural), and crypt damage (0=none, 
1=basal 1/3 damaged, 2=basal 2/3 damaged, 3=crypts loss, but 
surface epithelium present, 4=both crypts and surface epithe-
lium loss). Total histological score was defined as the sum of the 
three parameters.
Immunohistochemical (IHC) staining for GFP, using a Ve-
castain ABC kit (Vector Laboratories, Burlingame, CA, USA), 
was performed to identify the in vivo localization of trans-
planted BM-MSCs in the inflamed colon. Colonic tissue samples 
were incubated first with the primary anti-GFP antibody (Abcam, 
Cambridge, MA, USA) overnight at 4oC, then with a biotinylated 
secondary linking antibody, and finally with a streptavidin-
peroxidase complex for 1 hour. The final color product was de-
veloped using aminoethylcarbazole (Dako, Glostrup, Denmark). 
Sections were counterstained with hematoxylin, and tissues 
were photographed using an Olympus photomicroscope (Olym-
pus Corp., Tokyo, Japan).
5. Cytokine measurement
mRNA expression of inflammatory mediators, such as IL-
10, transforming growth factor β (TGF-β), and tumor necrosis 
factor α (TNF-α), in the inflamed colon was measured by real-
time polymerase chain reaction (PCR). Isolated colons were 
frozen in liquid nitrogen and stored at -70oC until use. Tissue 
samples were homogenized using a Polytron® System PT1200E 
(Kinematica AG, Luzern, Switzerland). Total RNA was extracted 
from the colonic tissues using a miRNeasy® Mini Kit (QIAGEN, 
Hilden, Germany) according to the manufacturer’s instructions 
and then reverse transcribed using the PrimerScriptTM RT Master 
Mix (Takara, Kusatsu, Japan). Template DNA was then amplified 
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by PCR using the Applied Biosystems (Foster City, CA, USA) 
StepOnePlusTM real-time PCR system and the following primers: 
5′-GGT TGC CAA GCC TTA TCG GA-3′ (IL-10 sense primer), 5′-
ACC TGC TCC ACT GCC TTG CT-3′ (IL-10 antisense primer), 5′-
TGA CGT CAC TGG AGT TGT ACG G-3′ (TGF-β sense primer), 
5′-GGT TCA TGT CAT GGA TGG TGC-3′ (TGF-β antisense 
primer), 5′-CAT CTT CTC AAA ATT CGA GTG ACA A-3′ (TNF-α 
sense primer), 5′-TGG GAG TAG ACA AGG TAC AAC CC-3′ 
(TNF-α antisense primer), 5′-CGC GGT TCT ATT TTG TTG GT-
3′ (Rn18S sense primer), 5′-AGT CGG CAT CGT TTA TGG TC-
3′ (Rn18S antisense primer). Thermal cycling conditions were 
30 seconds at 95oC, followed by 40 cycles of 5 seconds at 95oC, 
34 seconds at 60oC, and 15 seconds at 95oC. For relative quan-
tification, we compared the amount of target normalized to the 
Rn18S amplification.
6. Statistical analysis
Data are expressed as means±standard error of mean (SEM). 
Parametric and nonparametric analyses were performed using 
the Student t-test and Mann-Whitney U test, respectively. A 
value of p <0.05 was considered statistically significant for all 
tests. All statistical analyses were performed using SPSS version 
20.0 for Windows (IBM Corp., Armonk, NY, USA).
RESULTS
1. BM-MSCs injection induced prevention and rapid recovery 
of weight loss in DSS-induced chronic colitis 
We first investigated the clinical therapeutic efficacy of BM-
MSCs in a DSS-induced colitis model. Administration of 3% 
DSS in three cycles resulted in three peaks of colitis that were 
characterized by substantial weight loss and bloody diarrhea 
compared with the normal, untreated mice. However, DSS-
treated mice injected with BM-MSCs (BM-MSC-treated group) 
showed less weight loss than mice in the DSS-treated only 
group. Furthermore, body weight restoration was significantly 
promoted in BM-MSC-treated mice compared with the DSS-
treated only group. Significant differences were noted at days 
20 and 33 of the recovery periods of each DSS administration 
cycle (Fig. 1). In particular, regarding the course of weight 
change, BM-MSC injection in the first cycle of DSS administra-
tion showed a preventive effect on weight loss in the second 
cycle, and rapid restoration of weight loss rather than a preven-
tive effect in the third cycle, compared with the untreated DSS-
induced colitis group (Fig. 1).
Macroscopic examination also revealed that entire colons 
from the DSS-treated mice were short, hyperemic, and edema-
tous, indicating chronic inflammation in the colon. As shown 
in Fig. 2, BM-MSC treatment appeared to attenuate the colon 
shortening, though not to a statistically significant extent. 
In summary, injection of BM-MSCs in the first cycle showed 
a sustained beneficial effect throughout the three cycles of DSS 
administration.
2. BM-MSCs injection showed sustained histologic im-
provement in DSS-induced chronic colitis 
We sacrificed mice on day 33 for further evaluation of colon 
inflammation and crypt damage and microscopic evaluation 
of the long-term, anti-inflammatory effect of BM-MSCs. Colon 
tissue samples were microscopically examined following H&E 
staining. DSS-treated mice that were not treated with BM-MSCs 
showed severe infiltration of inflammatory cells and disruption 
of crypt architecture. BM-MSCs treatment of mice with DSS-
induced colitis exhibited a protective effect against DSS-induced 
histological damage, including fewer inflammatory infiltrates 
(less severe inflammation), a lower extent of inflammation, and 
less crypt structure damage, compared with untreated DSS-
induced colitis mice. DSS-treated mice transplanted with BM-
MSCs displayed significant reduction of total histological scores 
compared with scores for the DSS-treated only group (Fig. 3).
The IHC staining performed to identify transplanted BM-
MSCs in the colon on day 33 revealed no definite GFP positive 
cell in the colons of BM-MSC-injected chronic colitis mice (data 
not shown).
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Fig. 1. Clinical effects of bone marrow-derived mesenchymal stem 
cells (BM-MSCs) in repeated dextran sulfate sodium (DSS)-induced 
chronic colitis. Mice (n=5/group) received 3% dextran sulfate sodium 
(DSS) in their drinking water in a cyclic manner consisting of three 
cycles of DSS for 4 days/cycle and 6 days of normal water. Green 
fluorescent protein-transgenic mouse BM-MSCs were injected intra-
venously on days 1, 3, and 5 during the first cycle. DSS- and BM-
MSCs-treated mice showed a significant increase in body weight 
compared with DSS-only-treated mice. The data are presented as the 
mean±standard error of mean. *p<0.05 vs 3% DSS+BM-MSCs.
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3. BM-MSCs injection maintained anti-inflammatory cyto-
kine response in DSS-induced chronic colitis 
To identify the underlying mechanisms for the beneficial 
effect of BM-MSCs in DSS-induced chronic colitis, we inves-
tigated the influence of BM-MSC transplantation on pro- and 
anti-inflammatory cytokine production. Real-time PCR analysis 
of colonic tissues showed that mRNA expression of TNF-α was 
significantly increased in DSS-treated only mice and decreased 
in BM-MSC-treated mice with DSS-induced colitis. In contrast, 
mRNA expression of IL-10 and TGF-β was increased in the in-
flamed colons of BM-MSC-injected mice compared with that in 
colon samples of DSS-treated only mice. Notably, IL-10 produc-
tion, which is known to act as an anti-inflammatory regulatory 
cytokine,23,24 was significantly upregulated by about 10-fold in 
BM-MSC-treated mice, compared with DSS-treated only mice 
(Fig. 4).
DISCUSSION
In the present study, we identified the long-term beneficial 
role of BM-MSCs in the improvement of clinicopathologic ac-
tivity in a DSS-induced chronic colitis mouse model. Remark-
ably, initial injection of BM-MSCs at disease onset manifested 
a sustained beneficial effect throughout three cycles of DSS 
administration. Immunological assays indicated that the ef-
fect of BM-MSCs could be mediated by up-regulation of anti-
inflammatory cytokine, IL-10.
Due to their immunoregulatory function and differentiation 
potential, BM-MSCs are increasingly being used to treat au-
toimmune and systemic inflammatory disease. BM-MSCs are 
known to be immunoprivileged because of their low expression 
of class II major histocompatibility complex (MHC-II) and co-
stimulatory molecules in their cell surface, which makes them 
invisible to the immune system.10 Previous studies report that 
co-culture with MSCs influences cytokine production of T-cell 
subsets, which results in suppression of T-cell effector func-
tion (by decreasing levels of pro-inflammatory cytokines such 
as TNF-α, IFN-γ, IL-6, and IL-17) and enhancement of T-cell 
suppressor functions (by increasing IL-10 and TGF-β levels).25,26 
Similarly, because IBD is related to immune dysregulation, 
recent studies have considered immunomodulatory cytokines 
as therapeutic targets4,27 and BM-MSCs are emerging as one 
of the promising therapies for IBD. However, though accumu-
lating data have shown beneficial effects of BM-MSCs in an 
experimental colitis model,15,17,28,29 the mechanisms are yet to 
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Fig. 2. Effects of bone marrow-derived mesenchymal stem cells (BM-
MSCs) on macroscopic findings (A) and colon length (B). On day 33, 
the mice were sacrificed and their colons were removed from the 
cecum to the anus. The BM-MSC-treated, dextran-sulfate sodium 
(DSS)-induced colitis group showed a trend toward a lesser decrease 
in colon length compared with the DSS-treated group, but the differ-
ence did not reach statistical significance (control, untreated group 
7.5±0.6; 3% DSS-treated group 6.6±0.7; 3% DSS+BM-MSC-treated 
group 7.1±0.5). The colon length is presented as the mean±standard 
error of mean (*p<0.05). 
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Fig. 3. Histological improvement in bone marrow-derived mesenchymal stem cells (BM-MSCs)-transplanted, dextran-sulfate sodium (DSS)-induced 
chronic colitis. (A-F) Histological analysis was performed with H&E staining of colon tissues. (G) In the BM-MSC-treated, DSS-induced colitis 
group, total histological scores were significantly reduced compared with the DSS-only-treated group (control, untreated group 4.0±1.9; 3% DSS-
treated group 10.6±2.3; 3% DSS+BM-MSC-treated group 7.6±1.3; *p<0.05). The individual scores, including inflammatory severity, extent, and 
crypt damage, were also decreased with BM-MSC treatment compared with the scores of the DSS-only-treated group. The data are presented as 
the mean±standard error of mean. Representative histologic images are shown for the control group: A (×100) and D (×200); the 3% DSS-treated 
group: B (×100) and E (×200); and the 3% DSS+BM-MSC-treated group: C (×100) and F (×200).
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be determined. Furthermore, most of the studies focused on the 
prevention and improvement of acute gut inflammation by BM-
MSCs treatment.17,28,29 Therefore, in this study, we investigated 
the long-term effect of BM-MSCs specifically in chronic colitis 
induced by repeated DSS administration, which is an established 
experimental model for human IBD.30 
We found long-term beneficial effects of BM-MSCs on clini-
copathologic colitis activity in our chronic colitis model. In ad-
dition, with regard to the course of weight change, we found a 
greater preventive effect on weight loss in the second cycle of 
DSS administration and a more rapid restoring effect (without a 
preventive effect) in third cycle. These results suggest a decreas-
ing beneficial effect of BM-MSC treatment with the progression 
of time.
In regard to the potential mechanisms for the therapeutic 
effect of BM-MSCs suggested by experimental models of IBD, 
BM-MSCs have been reported to downregulate the expression 
of Th1-type cytokines15,17,28,29 and upregulate the population 
of FoxP3+ regulatory T cells, with a consequent increase in IL-
10 production.15,28,29,31 In agreement with previous studies, we 
showed a significant increase in IL-10 production in BM-MSC-
treated mice. IL-10, which is a signature cytokine for a subset 
of CD4 T cells that exhibit regulatory functions, induces Treg 
populations and attenuates experimental colitis.23,24 IL-10-se-
creting Treg cells are known to play a critical role in maintain-
ing intestinal homeostasis by suppressing immune response to 
resident commensal microbes.32 In addition, our results revealed 
that TGF-β levels also were increased in DSS-induced colitis 
mice that were treated with BM-MSCs, suggesting the possibil-
ity of FoxP3+ regulatory T cell induction23,24 and contribution to 
the intestinal repair process.16 
However, compared with previous studies that indicate BM-
MSC treatment downregulates the Th1-driven inflammatory 
responses in DSS-induced colitis mice,15,17 our data did not show 
a significant decrease in TNF-α levels upon BM-MSC trans-
plantation. DSS administration in the present study, as in other 
recent studies,15,17,28,29 increased the proinflammatory cytokine of 
TNF-α in inflamed mucosa, verifying the crucial role of TNF-α 
in the development of IBD.2,3 The lack of a definite inhibitory ef-
fect of Th1 response in BM-MSC-treated mice of our experiment 
might be attributable to the change of cytokine profiles accord-
ing to the acute or chronic stage of colitis. DSS-induced colitis 
is known to switch from Th1-Th17-mediated acute inflamma-
tion to a predominant Th2-mediated inflammatory response in 
the chronic state.33 In addition, because we used a chronic DSS-
induced colitis model to evaluate the long-term effect of BM-
MSCs, the recoverable extent of TNF-α might be lower than that 
expected in acute colitis and, therefore, we could not observe 
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Fig. 4. Effect of bone marrow-derived mesenchymal stem cells (BM-
MSCs) on the production of anti-inflammatory cytokines (IL-10 and 
TGF-β) (A, B) and pro-inflammatory cytokine, TNF-α (C). mRNA 
expression of inflammatory mediators was measured in colonic tis-
sue samples by using real-time polymerase chain reaction. BM-MSC 
treatment reduced the mRNA expression of tumor necrosis factor α 
and increased the mRNA expression of interleukin-10 and transform-
ing growth factor β. Similar results were obtained from three inde-
pendent experiments. The data are presented as the mean±standard 
error of mean (*p<0.05). 
DSS, dextran-sulfate sodium.
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significant suppressive effect of TNF-α expression after BM-
MSCs treatment. No significant improvement in colon length 
in our experiment could be also explained by chronic repeated 
injury by three cycles of DSS administration, which could con-
tribute to unrecoverable chronic injury like fibrosis.
The mechanism of the long-term effect of BM-MSCs is not 
likely due to long-term survival of injected BM-MSCs because 
we found no GFP positive cells in BM-MSCs-treated mice in our 
experiments and previous other studies demonstrate a rapid dis-
appearance of injected MSCs.17,28,29 However, given the reported 
long survival of T cells in peripheral tissues,34 long survival of 
regulatory T cells induced by initial injections of BM-MSCs 
could contribute to the long-term beneficial effect of BM-MSCs. 
Additional detailed experiments regarding the fate of BM-MSC-
induced regulated T cell population are needed to confirm this 
possibility.
In our study, we used chemically induced colitis model by 
DSS administration. Because acute, chronic, or relapsing model 
can be produced easily by changing the concentration of DSS, 
it is one of the most commonly used animal models for study-
ing IBD.33,35 However, as other animal models of genetically 
modified and adoptive transfer models, none of these models 
could represent the complexity of human disease. In addition, 
to date, there have been many experimental studies of the ef-
fects of MSCs in colitis models. However, we need more data 
about quality control of MSCs, different effects by different cell 
sources, and effective dose, frequency, and route based on the 
duration of effect for clinical application. Our data could give 
some information on the effect of MSCs with the progression of 
time.
In conclusion, we demonstrated that BM-MSC transplantation 
could be an effective means to treat chronic colitis in mice. In 
particular, initial systemic infusion of BM-MSCs at disease on-
set could exert preventive and rapid recovering effects through 
long-term immunosuppressive action in repeated DSS-treated 
chronic colitis. 
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